News Headlines Article

Amgen wins FDA approval for cholesterol drug Repatha
Los Angeles Times

The Food and Drug Administration has approved Amgen Inc.’s cholesterol-lowering medication, Repatha.

The move follows FDA’s approval last month for a similar drug Praluent, from Sanofi and partner Regeneron Pharmaceuticals Inc. Both Praluent and Repatha belong to a class of injectable cholesterol-lowering drugs known as PCSK9 inhibitors.

The FDA on Thursday approved Amgen’s Repatha for patients who are unable to control their cholesterol with existing drugs and treatments, specifically, adults with extremely high levels of LDL, or bad cholesterol, due to inherited conditions; and patients with persistently high LDL levels and a history of heart attack, stroke and other cardiovascular problems, according to the Associated Press.